Phase III clinical trial results from PRELUDE study, which explored the enzastaurin (Eli Lilly and Company; Lilly Oncology) as a monotherapy in the prevention of relapse in patients with diffuse large B-cell lymphoma (DLBCL), failed to show a statistically significant increase compared to placebo…Continue
Added by Peter Hofland, PhD on May 10, 2013 at 6:00am — No Comments
A new multi-center trial of high dose Interleukin-2 (HD rIL-2; Aldesleukin for Injection/Proleukin®; Prometheus Laboratories Inc, San Diego, CA/Novartis Vaccines and Diagnostics, Emeryville, CA) plus vemurafenib (Zelboraf®, Genentech/Roche) therapy in patients with BRAF V600 mutation-positive…Continue
Added by Peter Hofland, PhD on May 9, 2013 at 10:00am — No Comments
Data from various cancer registries in the United Kingdom shows that Bladder Cancer is a common cancer among men and women in the United Kingdom, with 10.335 new cases diagnosed in 2008.  It is one of the most frequently diagnosed cancer of the urinary system and accounts for 1 in every 30 new cases. With 7,390 new cases diagnosed in 2008, is a the 4th most common cancer in men  and 11th in women (2,945 female cases), giving a male: female ration of…Continue
Added by Peter Hofland, PhD on May 7, 2013 at 9:30pm — No Comments
Date presented at the 2013 Conference of The American Society of Breast Surgeons (ASBrS) shows promising results for non-surgical cryoablation treatment of breast cancer. The results were presented by Eisuke Fukuma, M.D., Ph.D., Chairman and Director of Breast Center, Director of Breast Disease Kameda Medical Center in Kamogawa City, Chiba, Japan.
Cryoablation, also be called percutaneous ablation,…Continue
Added by Peter Hofland, PhD on May 7, 2013 at 5:30pm — No Comments
Results of the ASPECCT ('763) trial, a phase III head-to-head study evaluating panitumumab (Vectibix®; Amgen Inc.) versus cetuximab (Erbitux®; ImClone LLC/Eli Lilly and Company and Bristol-Myers Squibb Company) as a single agent for the treatment of chemorefractory metastatic colorectal cancer (mCRC) in patients with wild-type KRAS tumors (n=1,010) met its primary endpoint…Continue
Added by Peter Hofland, PhD on May 7, 2013 at 3:00pm — No Comments
Results from a Phase II trial shows that ibrutinib (also known as PCI-32765; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one; Janssen Biotech, Inc. and Pharmacyclics), a first-in-class oral therapy that is a selective, irreversible, inhibitor of Bruton’s tyrosine kinase (BTK), offers rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of…Continue
Added by Peter Hofland, PhD on April 8, 2013 at 11:00am — No Comments
In a recently published study, neurosurgeons found that a new MRI-guided laser treatment used for the first time in a human study called NeuroBlate™ Thermal Therapy System (formerly known as AutoLITT™) a from of Laser Interstitial Thermal Therapy or LITT, offers them a new, safe and minimally invasive procedure for treating recurrent glioblastoma (GBM), a malignant type of brain tumor.
In the article, published in the April 5, 2013 online edition of the…Continue
Added by Peter Hofland, PhD on April 5, 2013 at 8:30am — No Comments
In breast cancer screening mammography has been proven to one of the most effective detection mechanisms available. Today, it is considered the only screening options that reduces mortality. However, while mammography is still the gold standard of breast cancer screening, reports show that there is increasing awareness of subpopulations of women for whom mammography has reduced sensitivity. Furthermore, over the last decade, mammography has created much debate because of observed false…Continue
Added by Peter Hofland, PhD on April 4, 2013 at 5:30pm — No Comments
Drugs classified as poly (ADP-ribose) polymerase (PARP) inhibitors have been shown to be promising anticancer agents for breast and ovarian cancers deficient in either BRCA1 or BRCA2. Now, according to data from a preclinical study published in the April 1, 2013 issue of Cancer Research, a journal of the American Association for Cancer Research,…Continue
Added by Peter Hofland, PhD on April 3, 2013 at 3:30pm — No Comments
MicroRNAs are short non-coding RNAs that posttranscriptionally modulate the expression of multiple target genes. They are implicated in a wide range of cellular and developmental processes. The microRNA (miR-155), a short, single strand of ribonucleic acid encoded by the miR-155 host gene, is highly expressed in both activated B and T cells and in monocytes/macrophages. Research has shown that miR-155 levels change dynamically during both hematopoietic lineage differentiation and the…Continue
Added by Peter Hofland, PhD on April 1, 2013 at 4:00pm — No Comments
To improve the prognosis of patients with pancreatic cancer, a more accurate serum diagnostic method is required. Now researchers have developed a new diagnostic test that uses a scientific technique known as metabolomic analysis that may be a safe and easy screening method.The researchers believe that this new test may improve the prognosis, offering patients with pancreatic cancer a real survival advantage through earlier detection.
According to data from the…Continue
Added by Peter Hofland, PhD on March 29, 2013 at 9:30am — No Comments
A first long-term study of the full-population health impacts of the closure of nuclear reactor in the United States found 4,319 fewer cancers over 20 years, with declines in cancer incidence in 28 of 31 categories (14 of them statistically significant), including notable drops in cancer for women, Hispanics and children.
In their article, published Biomedicine International, an open access peer-reviewed…Continue
Added by Peter Hofland, PhD on March 28, 2013 at 10:30am — No Comments
Results from a behavioral research study designed to learn more about mood and physiological responses in different groups of people attempting to quit smoking published in the March 27 edition of JAMA Psychiatry shows that smokers have a higher probability of quitting smoking and a better overall cessation experience when taking varenicline compared to bupropion and to placebo or unmedicated…Continue
Added by Peter Hofland, PhD on March 27, 2013 at 4:00pm — No Comments
According to projections published in the Journal Cancer Epidemiology, Biomarkers & Prevention, the number of people who have survived cancer will rise by 31% from 13.7 million today to nearly 18 million in 2022 (8.8 million males and 9.2 million females). The increased number of cancer survival is the result of the considerable progress that has been made in reducing cancer incidence. The review shows that among the 3 most…Continue
Added by Peter Hofland, PhD on March 27, 2013 at 3:00pm — No Comments
Food is an important factor in determining cancer incidence. Generally, vegetables rich in antioxidants and fibers tend to reduce the development of cancer, while fat-rich food may be associated with increases in breast, colon and prostate cancers. Other factors. such as a sedentary lifestyle and high calorie diet, are also associated with the development of cancer.
A major new study that tracked the diets and disease rates of nearly 380,000 people over 13 years, shows…Continue
Added by Peter Hofland, PhD on March 27, 2013 at 12:30pm — No Comments
A new a double-blind, randomized Phase 2b clinical trial of CV9104 (CureVac GmbH) for the treatment of patients with castration-resistant prostate cancer will enroll up to 200 patients in eight European countries.The purpose of this study is to determine whether the new RNActive-derived prostate cancer vaccine prolongs survival in patients with asymptomatic or minimally symptomatic metastatic prostate cancer that is castrate…Continue
Added by Peter Hofland, PhD on March 27, 2013 at 7:30am — No Comments
Transforming rearrangements of the ALK (anaplastic lymphoma kinase) gene define a unique subset of patients with non–small cell lung carcinoma (NSCLC). While ALK gene rearrangements affect only about 4% of all lung cancers, they are more frequent in adenocarcinomas, in never or light smokers, and seem almost mutually exclusive with activating EGFR or KRAS mutations. Today, the clinical success of the anaplastic lymphoma kinase (ALK) inhibitor crizotinib (…Continue
Added by Peter Hofland, PhD on March 26, 2013 at 2:30pm — No Comments
Data published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research shows that baldness is associated with an increased risk of prostate cancer among African-American men. According to published data, publication also showed that risk for advanced prostate cancer increased with younger age and type of baldness.
Prostate cancer is the second leading cause of cancer death in American men, behind only lung…Continue
Added by Peter Hofland, PhD on March 26, 2013 at 2:30pm — No Comments
One of the most important cancer screening procedure for colorectal cancer (CRC) prevention in people over 50 or those with high risk factors is a colonoscopy. The primary goal of a colonoscopy is to prevent deaths from colon cancer. Screening may help identify cancers at an early and potentially treatable stage. Some tests can also prevent the development of cancer by identifying precancerous abnormal growths called adenomatous polyps. In most cases, these polyps can be removed before…Continue
Added by Peter Hofland, PhD on March 26, 2013 at 10:00am — No Comments
Researchers at the University of California, San Diego Moores Cancer Center have identified a humanized monoclonal antibody specific for CD44 (RG7356) that targets and directly kills chronic lymphocytic leukemia (CLL) cells. The adhesion molecule CD44 is a transmembrane glycoprotein that is overexpressed in a number of solid tumor and hematologic malignancies and is associated with a poor prognosis. The findings, published in…Continue
Added by Peter Hofland, PhD on March 25, 2013 at 6:30pm — No Comments